Related Experiment Video
Updated: May 1, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
What is new in fungal pharmacotherapeutics?
Abstract:
Approximately 20-25% of the population worldwide is affected by superficial cutaneous mycoses (SCM). SCM are cutaneous fungal infections with a wide array of systemic and topical treatment options. However, successful therapeutic outcomes are limited by patient non-adherence, medication side effects, potential drug interactions, antifungal resistance and disease recurrence. Advances in formulation technology have allowed for the development of more effective and safer therapies. In this article we will review several new and emerging pharmacotherapeutics for onychomycosis and tinea pedis.
Related Concept Videos
Antifungal Agents
Overview of Fungi
Fungal Phylum Microsporidia
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacogenomics: Identification of New Drug Targets
Fungal Phylum Ascomycota

